Tag: PD-1
-
Immunotherapy Advances in SCLC: Promise, Limitations, and Biomarker Needs
Overview: Immunotherapy’s Emerging Role in SCLC Small cell lung cancer (SCLC) has long challenged clinicians with its aggressive biology and tendency for rapid relapse. In recent years, immunotherapy has emerged as a beacon of hope, offering meaningful efficacy gains in several lines of treatment. This article reviews the current state of immunotherapy in SCLC, highlighting…
-
Immunotherapy for HIV: Early PD-1 Treatment Shows Potential for Drug-Free Viral Control
Overview: A new immunotherapy approach in HIV Researchers report promising safety data from the first-in-human trial of an anti-PD-1 antibody, budigalimab, in people living with HIV. The study, published in Nature Medicine, explored whether a cancer immunotherapy could be used at low doses to augment the immune system’s ability to control HIV without daily antiretroviral…
-
Immunotherapy Trial: PD-1 Inhibitor Budigalimab Shows Potential for Drug-Free HIV Control
New Immunotherapy Approach Sparks Hope for HIV Management Researchers have taken a bold step in the hunt for HIV strategies that could reduce or even eliminate the need for daily antiretroviral therapy (ART). A first-in-human, randomized, placebo-controlled Phase 1b trial published in Nature Medicine explored budigalimab, a monoclonal antibody that targets the PD-1 protein, a…
-
Immunotherapy for HIV: Early Trials of Anti-PD1 Drug Budigalimab Suggest Drug-Free Viral Control
Immunotherapy Offers a New Avenue in HIV Management Researchers are cautiously optimistic about a novel immunotherapy approach that could one day reduce or even eliminate the need for daily HIV medications. In a first-in-human Phase 1b trial, budigalimab, a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) pathway, was tested in people…
-
Engineered Salmonella therapy delivers immune payloads to combat cancer
Breakthrough in bacterial immunotherapy: ACTM-838 targets solid tumors Solid tumors have long posed a challenge for immunotherapy, often creating an immune-suppressive microenvironment that thwarts even the most advanced treatments. A new study published in Oncotarget (Volume 16, October 6, 2025) introduces ACTM-838, a novel systemically delivered bacterial immunotherapy designed to enrich in solid tumors and…
-
Pembrolizumab Doubles Survival in Advanced Head and Neck Cancer
The Breakthrough: A New Immunotherapy Redefines Outcomes in Locally Advanced Head and Neck Cancer Locally advanced head and neck cancer poses a formidable challenge. In many patients, the disease is detected at a stage where surgery, radiotherapy, and chemotherapy are the mainstays of treatment, yet recurrence and progression remain common. A recent advance in immunotherapy,…